Post by IQVIA

Rare disease success depends on the evidence you can defend. Patient meaningful endpoints are critical to demonstrating treatment benefit, reducing regulatory uncertainty, and supporting payer and HTA decisions. Our new article and COA Rare Disease Guide show how fit for purpose COA strategies help generate decision grade evidence for approval, value assessment, and access. Learn more: https://lnkd.in/dwbAn6mh